New‐onset retroperitoneal fibrosis following COVID‐19 mRNA vaccination: Coincidental or vaccine‐induced phenomenon?

Abstract

The Pfizer‐BioNTech mRNA vaccine is a US Food and Drug Administration‐approved coronavirus disease 2019 (COVID‐19) vaccine. Although it is reported to be safe and effective, immune dysregulation leading to autoimmunity has become an area of concern. Retroperitoneal fibrosis (RPF) is an immune‐mediated fibroinflammatory disease characterized by the deposition of fibrous tissues, primarily around the abdominal aorta and iliac arteries. Herein, we report a case of RPF following Pfizer BioNTech COVID‐19 mRNA vaccination. To the best of our knowledge, there have been no published reports on RPF after COVID‐19 mRNA vaccination. A 58‐year‐old woman with no history of autoimmune diseases presented with acute onset of epigastric pain 5 weeks after the second dose of the Pfizer‐BioNTech vaccine. She had been diagnosed with stage I breast cancer 9 years ago and was in complete remission on admission. Abdominal computed tomography showed preaortic soft‐tissue infiltration around the origin of the superior mesenteric artery but no evidence of breast cancer recurrence. Considering the temporal relationship between current symptoms and vaccination and the absence of other possible causes, she was diagnosed with RPF secondary to Pfizer‐BioNTech vaccine‐induced autoimmunity. This case may raise awareness of the possibility of RPF development following COVID‐19 mRNA vaccination.